Table 2.
Baseline functional capacity and hemodynamics of patients at time of inclusion.
| n | Last measurement before riociguat treatment | |
|---|---|---|
| Exercise capacity | ||
| WHO FC (n (%)) | 36 | |
| I | 0 (0) | |
| II | 0 (0) | |
| III | 19 (52.8) | |
| IV | 17 (47.2) | |
| 6MWD (m) | 26 | 389 ± 108 |
| Hemodynamics and NT-proBNP | ||
| mPAP (mmHg) | 36 | 49 ± 12 |
| PAWP (mmHg) | 36 | 9 ± 4 |
| CO (L/min) | 36 | 4.3 ± 1.3 |
| CI (L/min/m2) | 36 | 2.2 ± 0.6 |
| PVR (dyn·s·cm–5) | 36 | 956 ± 501 |
| NT-proBNP (ng/L) (median (IQR)) | 31 | 1137 (283–2142) |
Values are given as mean ± SD unless otherwise indicated.
WHO, World Health Organization; FC, functional class; 6MWD, 6-min walking distance; mPAP, mean pulmonary artery pressure; PAWP, pulmonary arterial wedge pressure; CO, cardiac output; CI, cardiac index; PVR, pulmonary vascular resistance; NT-proBNP, N-terminal fragment of pro-brain natriuretic peptide.